Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of 'Buy' from Analysts

Arcus Biosciences, Inc. (NYSE:RCUS) has garnered a consensus recommendation of "Buy" from the nine research firms monitoring the company, according to reports from various financial analysts. Out of these firms, one analyst has suggested holding the stock, while seven analysts have provided buy ratings and one has issued a strong buy recommendation. The average price target for the stock over the next year is estimated to be $31.29.

Several research reports have been released concerning RCUS. For instance, HC Wainwright lowered its target price for Arcus Biosciences from $20.00 to $18.00 while assigning a "neutral" rating. Conversely, Wedbush maintained an "outperform" rating and set a target price of $36.00 in a research note dated November 7. Barclays also revised its target price upwards, from $25.00 to $29.00, labeling the stock as "overweight" in a report released on October 25. Meanwhile, Morgan Stanley decreased its price target from $36.00 to $25.00, rating the stock as "overweight" as well.

Insider Transactions at Arcus Biosciences

In recent insider trading news, CFO Robert C. Goeltz II sold 3,594 shares on December 31, which fetched a total of $53,910 at an average price of $15.00 per share. Following this transaction, he retains ownership of approximately 60,138 shares, valued around $902,070, reflecting a 5.64% decrease in his total holdings. This insider trade has been reported to the Securities and Exchange Commission and is available publicly.

Institutional Investor Involvement

Multiple large institutional investors have recently bought and sold shares of Arcus Biosciences. For example, Woodline Partners LP increased its holdings by 1.3% in the last quarter, now owning 3,523,937 shares, which are valued at about $52,471,000 after purchasing an additional 45,497 shares. Another prominent investor, Two Sigma Advisers LP, raised its stake by 35.8%, acquiring an additional 15,500 shares which now total 58,800 shares valued at $876,000. Furthermore, ProShare Advisors LLC saw a 44.4% increase in its holdings, taking ownership of 16,379 shares valued at around $244,000. In total, institutional investors control approximately 92.89% of the company's stock.

Stock Performance Overview

On the trading front, shares of RCUS experienced a decline of 16.1%, trading down by $2.11 to hit $11.00. During trading, about 4,655,000 shares exchanged hands, notably surpassing the average volume of 739,628. Over the past year, the stock has reached a low of $10.65 and a high of $20.31. Currently, Arcus Biosciences boasts a market capitalization of $1.01 billion, a price-to-earnings ratio of -3.49, and a beta value of 0.84. The company’s fifty-day moving average price stands at $14.41, while the 200-day moving average is $15.66. Its financial ratios indicate a debt-to-equity ratio of 0.08 and both current and quick ratio of 5.24.

About Arcus Biosciences

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative cancer treatments in the United States. Its portfolio includes pipeline products such as Domvanalimab, which is an anti-TIGIT antibody currently undergoing Phase 2 and Phase 3 clinical trials, and AB308, an investigational anti-TIGIT monoclonal antibody that is in a Phase 1b clinical trial exploring treatments for advanced solid and hematologic malignancies.

stocks, buy, analysts